Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel cytochrome b5 inhibitors and their use in sickle cell disease

Sep. 22, 2004

Pfizer scientists describe new cannabinoid CB1 antagonists

Sep. 22, 2004

Metabolic completes dosing in AOD-9604 phase IIb trial

Sep. 22, 2004

Sumitomo licenses Japanese rights to repaglinide

Sep. 22, 2004

European marketing authorization submitted for once-monthly oral formulation of Bonviva

Sep. 21, 2004

Complete response for Symlin submitted to FDA

Sep. 21, 2004

BMS scientists identify new calcium-sensing receptor antagonists

Sep. 21, 2004

Involvement of neural histamine in energy homeostasis

Sep. 20, 2004

GIP receptor antagonist improves glucose tolerance and insulin resistance in vivo

Sep. 20, 2004

Approvable letter for Angeliq

Sep. 20, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...